Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tadalafil Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

NCT05051436
View directory record Official record
Conditions
Pre-diabetes, Obesity
Interventions
Mirabegron 50 MG, Tadalafil 10 MG, Placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT01178073
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
ambrisentan, tadalafil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 17, 2026, 1:56 AM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.

NCT00734604
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
tadalafil once a day [T(OaD)], sildenafil citrate as needed [S(PRN)], tadalafil as needed [T(PRN)]
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Huntsville, Alabama • Newport Beach, California • Middlebury, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 17, 2026, 1:56 AM EDT
Withdrawn Phase 4 Interventional

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

NCT03309592
View directory record Official record
Conditions
Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
Interventions
Ambrisentan Pill, Tadalafil Pill
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)

NCT02058095
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 17, 2026, 1:56 AM EDT
Not listed Phase 4 Interventional

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction

NCT02225548
View directory record Official record
Conditions
Parkinson's Disease, Erectile Dysfunction
Interventions
Selegiline, Tadalafil
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 64 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 17, 2026, 1:56 AM EDT
Recruiting Phase 3 Interventional

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

NCT05206955
View directory record Official record
Conditions
Fontan Palliation
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

NCT04235270
View directory record Official record
Conditions
Healthy
Interventions
FDC of Macitentan and Tadalafil, Macitentan, Tadalafil
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Tadalafil, Placebo, Finasteride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Davis, California • Fresno, California • Laguna Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 17, 2026, 1:56 AM EDT
Withdrawn No phase listed Observational

Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults

NCT05458232
View directory record Official record
Conditions
Sarcopenia
Interventions
Tadalafil 5mg
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

NCT00125918
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Tucson, Arizona • Minneapolis, Minnesota • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Not applicable Interventional Results available

Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

NCT00843635
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Tadalafil, Placebo
Drug · Other
Lead sponsor
Donald T. Weed
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 17, 2026, 1:56 AM EDT
Active, not recruiting Phase 2 Interventional

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

NCT05709574
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Tadalafil 20 MG
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

NCT02819440
View directory record Official record
Conditions
Healthy, Obese
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 50 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Early Phase 1 Interventional

Tadalafil and Sildenafil for Duchenne Muscular Dystrophy

NCT01359670
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Tadalafil, Sildenafil
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
7 Years to 15 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 17, 2026, 1:56 AM EDT
Completed No phase listed Observational Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

NCT05039086
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PDE5 inhibitor, Endothelin Receptor Antagonists
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
13,021 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2623091 in Participants With High Blood Pressure

NCT02194465
View directory record Official record
Conditions
Primary Hypertension
Interventions
LY2623091, Tadalafil, Spironolactone, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
Glendale, Arizona • Concord, California • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

NCT04984993
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
MED3000 (Male), Tadalafil 5mg (Male), MED3000 (Female), Tadalafil 5mg (Female)
Device · Drug
Lead sponsor
Futura Medical Developments Ltd.
Industry
Eligibility
22 Years to 70 Years · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

Tadalafil in Subjects With Mild to Moderate Hypertension

NCT00157326
View directory record Official record
Conditions
Hypertension
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2007 · Synced Oct 17, 2026, 1:56 AM EDT
Recruiting Phase 2 Interventional

Vasodilator and Exercise Study for DMD (VASO-REx)

NCT06290713
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in Children, Vasodilation, Exercise, DMD
Interventions
Tadalafil, Placebo, Exercise Training
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
6 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Actual Use Trial of Tadalafil 5 mg

NCT06805513
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tadalafil 5 mg tablets with a digital tool.
Combination Product
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 1:56 AM EDT
Terminated Phase 4 Interventional Results available

Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study

NCT01272388
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 17, 2026, 1:56 AM EDT
Recruiting Phase 2 Interventional

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

NCT05937854
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Aurora, Colorado • Decatur, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 1:56 AM EDT